COVID-19 Treatment at a Glance.

As coronavirus disease 2019 (COVID-19) spreads across the world, the ongoing clinical trials are leading to a big race worldwide to develop a treatment that will help control the pandemic. Unfortunately, COVID-19 does not have any known effective treatment with reliable study results yet. In this pandemic, there is not a lot of time to develop a new specific agent because of the rapid spread of the disease. The process of developing a vaccine is long and requires hard work. Although the pathophysiology of the disease is not fully understood, some of the proposed treatment alternatives are based on old evidence and some have been used with the idea that they might work owing to their mechanism of action. The efficacy, reliability, and safety of the currently available treatment alternatives are therefore a matter of debate. Currently, the main therapies used in the treatment of COVID-19 are antiviral drugs and chloroquine/hydroxychloroquine. Other proposed options include tocilizumab, convalescent plasma, and steroids, but the mainstay of the treatment in intensive care units remains supportive therapies.

What We Learned about COVID-19 So Far? Notes from Underground.

The novel coronavirus pandemic poses a major global threat to public health. Our knowledge concerning every aspect of COVID-19 is evolving rapidly, given the increasing data from all over the world. In this narrative review, the Turkish Thoracic Society Early Career Taskforce members aimed to provide a summary on recent literature regarding epidemiology, clinical findings, diagnosis, treatment, prevention, and control of COVID-19. Studies revealed that the genetic sequence of the novel coronavirus showed significant identity to SARS-CoV and MERS-CoV. Angiotensin-converting enzyme 2 receptor is an important target of the SARS-CoV-2 while entering an organism. Smokers were more likely to develop the disease and have a higher risk for ICU admission. The mean incubation period was 6.4 days, whereas asymptomatic transmission was reported up to 25 days after infection. Fever and cough were the most common symptoms, and cardiovascular diseases and hypertension were reported to be the most common comorbidities among patients. Clinical manifestations range from asymptomatic and mild disease to severe acute respiratory distress syndrome. Several patients showed typical symptoms and radiological changes with negative RT-PCR but positive IgG and IgM antibodies. Although radiological findings may vary, bilateral, peripherally distributed, ground-glass opacities were typical of COVID-19. Poor prognosis was associated with older age, higher Sequential Organ Failure Assessment score, and high D-dimer level. Chloroquine was found to be effective in reducing viral replication in vitro. Likewise, protease inhibitors, including lopinavir/ritonavir, favipiravir, and nucleoside analogue remdesivir were proposed to be the potential drug candidates in COVID-19 management. Despite these efforts, we still have much to learn regarding the transmission, treatment, and prevention of COVID-19.

The free neural grafting for recurrent nerve laceration Experimental study in rabbit.

AIM: The most dreaded complication of thyroidectomy is recurrent laryngeal nerve damage, which is most of the time hardly irreversible. In our experimental study we researched the use of free nerve grafts in the treatment of laryngeal nerve damage in rabbit. MATERIAL AND METHODS: There were three groups in our study. In the first group, the recurrent laryngeal nerve was severed and then a free nerve graft was interposed between the phrenic nerve and distal end of recurrent laryngeal nerve. In the second group, a defect in the continuity of the laryngeal nerve was created. The two ends of the nerve were joined together later by an interposed free nerve graft. In the third group, only a defect in the recurrent nerve was created without any attempt at uniting the ends together so that these latter subjects could be assigned as control group. In the evaluation process we performed laryngeal endoscopy, laryngeal EMG and histopathologic examination. RESULTS: On the 21. day of trial, in the first and second group vocal cord movements were detected on the laryngoscopy along with regeneration waves on EMG. In the third group there was no vocal cord movements on the side where a neural damage was created intentionally. On EMG there was degeneration waves as opposed to regeneration waves seen in the first and second groups. Histopathologic findings were similar. CONCLUSIONS: Recurrrent laryngeal nerve paralysis is an unwanted complication because it causes permenant sequela. Studies which intend to find a cure for this complication are increasing in number. We aim to find new approaches to cure patients suffering from this devastating complication as well. In our exprerimental study, vocal cord movements were reproduced without causing diaphragmatic paralysis. We believe the results of our study promise to relieve the suffering of patients. The results are encouraging. KEY WORDS: Muscle, Rat model, Reinnervation, Surgery.